Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential

,

GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library,” is available online and will appear in the upcoming issue of the peer-reviewed scientific journal mAbs.

Read the full press release.

GigaGen Announces New Office Space in South San Francisco

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art laboratory space to accommodate the company’s expanding research and development activities and hiring plans for 2018 and beyond. GigaGen completed relocation to One Tower Place in late December 2017.

Read the full press release.

GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin (rIVIG) therapy for patients with primary immunodeficiency diseases (PI) that overcomes many of the limitations of current plasma-based IVIG options.

Read the full press release.

GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, CTLA-4, TIGIT, TIM-3, GITR, PD-L1, B7-H3, TLR2 and TLR4.

Read the full press release.

GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif.

Read the full press release.

GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming issue.

Read the full press release.

GigaGen closes $50M deal with Grifols

,

GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols.

Read the full story from Endpoints:

An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies

,

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform.

Read the full press release.

GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies

,

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development of oncology drugs from mouse and human B cell repertoires using GigaGen’s novel massively parallel drug discovery technology.

Read the full press release.

GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio

,

Listen to Moira Gunn’s interview with Dave Johnson, PhD, CEO of GigaGen on “Creating a Synthetic Immune System” on Biotech Nation Radio.